替索妥单抗维多汀联合卡铂、帕博利珠单抗或贝伐珠单抗治疗复发性或转移性宫颈癌:innovaTV 205/GOG-3024/ENGOT-cx8 研究结果
这项开放标签多中心 Ib/II 期研究评估替索妥单抗维多汀(TV)联合贝伐珠单抗、帕博利珠单抗或卡铂治疗复发性或转移性宫颈癌。剂量扩展期 101 例中,一线 TV 联合卡铂客观缓解率为 54.5%(18/33;95%CI 36.4–71.9),一线 TV 联合帕博利珠单抗为 40.6%(13/32;95%CI 23.7–59.4),二/三线 TV 联合帕博利珠单抗为 35.3%(12/34;95%CI 19.7–53.5)。
要点
- 剂量递增期 41 例未观察到剂量限制性毒性,推荐 II 期剂量为 TV 2 mg/kg 联合贝伐珠单抗 15 mg/kg、帕博利珠单抗 200 mg 或卡铂 AUC 5,均第 1 天每 3 周一次。
- 剂量扩展期一线 TV 联合卡铂客观缓解率 54.5%,一线 TV 联合帕博利珠单抗 40.6%,二/三线 TV 联合帕博利珠单抗 35.3%。
- 中位缓解持续时间在联合卡铂组为 8.6 个月、联合帕博利珠单抗一线组未达到、二/三线组为 14.1 个月。
核心结论
- TV 联合贝伐珠单抗、卡铂或帕博利珠单抗在初治和经治复发性或转移性宫颈癌中显示出可控的安全性和令人鼓舞的抗肿瘤活性。
研究设计与样本
- 开放标签、多中心 Ib/II 期研究(ClinicalTrials.gov 标识号 NCT03786081),共入组 142 例患者。
- 剂量递增期(n=41)评估剂量限制性毒性并确定 TV 联合贝伐珠单抗(A 组)、帕博利珠单抗(B 组)或卡铂(C 组)的推荐 II 期剂量。
- 剂量扩展期(n=101)在推荐 II 期剂量下评估 TV 联合卡铂一线治疗(D 组)、联合帕博利珠单抗一线治疗(E 组)或二/三线治疗(F 组)的抗肿瘤活性与安全性。
- 剂量扩展期的主要终点为客观缓解率。
主要发现
- 剂量递增期未观察到剂量限制性毒性。
- 剂量扩展期 D 组客观缓解率为 54.5%(n/N,18/33;95%CI 36.4–71.9)。
- 剂量扩展期 E 组客观缓解率为 40.6%(n/N,13/32;95%CI 23.7–59.4)。
- 剂量扩展期 F 组客观缓解率为 35.3%(12/34;95%CI 19.7–53.5)。
- D 组、E 组和 F 组的中位缓解持续时间分别为 8.6 个月、未达到和 14.1 个月。
关键数值与推荐
- 推荐 II 期剂量为 TV 2 mg/kg 联合贝伐珠单抗 15 mg/kg 第 1 天每 3 周一次、帕博利珠单抗 200 mg 第 1 天每 3 周一次或卡铂 AUC 5 第 1 天每 3 周一次。
- D 组(一线 TV 联合卡铂)≥3 级不良事件(≥15%)为贫血、腹泻、恶心和血小板减少。
- F 组(二/三线 TV 联合帕博利珠单抗)≥3 级不良事件(≥15%)为贫血。
- E 组(一线 TV 联合帕博利珠单抗)无≥15%的≥3 级不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). METHODS: This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). RESULTS: A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade ≥3 adverse events (≥15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none ≥15%, arm E). CONCLUSION: TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.
引用
- Vergote I, Van Nieuwenhuysen E, O'Cearbhaill RE, et al. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. J Clin Oncol. 2023. PMID: 37651655. doi:10.1200/JCO.23.00720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。